



2

3

4

Highlights

Financial results


Portfolio performance

Strategy

Annexure

Further information on terms used in this announcement is available at <u>https://omnibridgeway.com/investors/omni-bridgeway-glossary</u> ("Notes" and "Glossary").

The Notes and the Glossary contain important information, including definitions of key concepts, and should be read in conjunction with this presentation.





Result snapshot

For the 6 months ended 31 December 2021



Record first half income \$127.1m

Driven by 31 completions and a 2Q22 skew Income yet to be recognised¹ ~\$160m



Conversion rate 16% 3 year rolling average³





New commitments² \$190m 37% of FY22 target plus \$151m new opportunities across 29 exclusive term sheets

Estimated portfolio value (EPV)² \$23.2bn Up 15% on 30 June 2021 Fu

Funds under management \sim \$2.4bn with 40% yet to be committed

Investments² 297 <4% directly on balance sheet

Implied embedded value (IEV)⁴ \$3.1bn

Up 10% on 30 June 2021

ζ<u>ζ</u>

Strong cash and receivables \$313.7m

Driven by key completions and collection of receivables

Financial results Portfolio

Highlights

1. This potential income relates to investments, with an aggregate EPV of \$2.2bn and possible completions in FY22 and FY23, which are substantially completed but did not fully satisfy the revenue recognition accounting standards and our policies.

Includes conditional and Investment Committee approved investments. Excludes Fund 6 conversion of EPV to gross investment income.

Excludes conditional and Investment Committee approved investments

Record first half income production

- \$127m income achieved from diversified sources in 1H22 generating more stable income with 3Q22 completions looking strong
- There have been numerous successful judgments and agreed settlements that may generate an additional ~\$160m income in subsequent periods
- First generation funds (Fund 1 and Funds 2&3) are transitioning from NCI payments to returns to OBL shareholders in FY23 or potentially earlier subject to future drawdowns in Funds 2&3
- Continued progress on investment completions in Fund 1 such that OBL expects to start receiving returns in 2022
 - ~\$37m in priority returns remaining outstanding to our Fund investor (NCI) at 31 December 2021
 - ~\$28m of income yet to be recognised from identified completions and cash at bank of ~\$9m
- 🕑 Second generation funds demonstrate good progress with returns and fees generated when the funds are more mature, and performance crystallises the outcome 🥎 from the waterfall
- A portfolio income conversion rate of 10% in 1H22 is lower than the long-term conversion rate of 15% due to some early investment completions in Fund 4 and an adverse financial result in two settlements in Fund 5
- Continued focus on selection of high-quality investments driving growth in portfolio with FY22 commitment target expected to be achieved
- Debt refinancing remains on track to occur in 2022 with key commercial terms finalised with a proposed lender subject to completing final legal due diligence, documentation and syndication
- Successful transition with the appointment of Michelle Painter SC to the Australian Investment Committee in December 2021 following founder Hugh McLernon's retirement
- Australian class action reform legislation, which was introduced into Parliament in 2021 (but has not yet been passed by the Senate), has been delayed until after the Federal election
- No impact yet seen on Court activity in the US or elsewhere from the prevalence of the Omicron variant

Financial results

\$m	1H21	1H22	Change from 1H21	
Litigation investments – intangible proceeds	43.9	108.6	147%	
Litigation investments – claims portfolio proceeds	<0.1	3.4		
Litigation investments – purchased claims proceeds	<0.1	3.6		
	43.9	115.5	163%	
Management fees	1.4	3.2	130%	
Interest revenue and other	5.0	8.1	69%	
	50.3	127.1	153%	
Litigation investments – cost derecognised / amortised	(34.8)	(69.6)	100%	
Litigation investments – purchased claims disposed	<0.1	(3.4)		
	(34.8)	(73.0)	110%	
Net income / gain	15.5	54.1	249%	
Impairment expense	(107.0)	(29.7)	72%	▼
Overheads – employee expenses and corporate office expenses	(36.6)	(38.2)	4%	
Adverse costs	(13.9)	(1.3)	91%	▼
Other expenses	(12.4)	(5.7)	54%	▼
Fair value adjustments on financial liabilities	10.0	2.4	76%	▼
Profit / (loss) before tax	(144.4)	(18.4)	87%	
Income tax benefit /(expense)	33.5	9.6		
Profit / (loss) after tax	(110.8)	(8.7)	92%	
Other comprehensive income for the period, net of tax	(42.5)	10.1	123%	
Total comprehensive income / (loss) for the period	(153.3)	1.4	101%	
	30 June 2021	31 December 2021	Change fro 30 June 20	
Cash and cash equivalents	142.6	165.7	50 June 20	21
Receivables from litigation contracts	197.6	148.0		
Cash and net receivables	340.2	313.7	8%	▼
Litigation contracts in progress (intangible assets)	391.0	357.3		
Other litigation investment assets	133.8	137.6		
Net assets	762.3	683.4	10%	▼
Number of shares	262.2	265.0		
Net asset backing (\$ per share)	2.9	2.6		
Estimated portfolio value ¹	\$20.1bn	\$23.2bn	15%	
Implied embedded value ²	\$2.8bn	\$3.1bn	10%	
Number of investments ¹	323	322	-	

Financials

- Statutory comprehensive income of \$1.4m driven by: ٠
 - Net income / gain of \$54.1m
 - Management fees, up 130%
 - ~74% lower impairment and adverse cost provisions
- \$29.7m provision for impairments mainly represented by unsettled component • of Wivenhoe investment
- Operational cash expenditure has remained relatively flat despite growth in EPV •
- Management fees cover ~8% of net operational cash expenditure

OBL financial position

• Strong financial position maintained with cash and receivables of ~\$209m on OBL balance sheet, sufficient to support corporate initiatives

Wivenhoe

\$85m potential upside from settlement of the remaining 50% portion of the liability • allocated to Seqwater, subject to appeals and other court processes, with no adverse cost risk nor ongoing costs if successful on appeal

1. Includes conditional and Investment Committee approved investments

2. Excludes conditional and Investment Committee approved investments.

Financial results

Investment income¹

	Dalassa			Funds				
\$m	Balance sheet	1	2&3	4	5	6	7	Total
Investment income								
Investments completed in 1H22	8.0	26.5	4.2	36.8	-	9.5	-	85.0
Investments completed in prior periods	1.7	0.1	-	-	(0.6)	0.9	-	2.1
Ongoing investments	-	8.8	6.7	3.3	-	9.6	-	28.4
Total income recognised ² in 1H22	9.7	35.4	10.9	40.1	(0.6)	20.0	-	115.5
Binding conditional settlements	18.0 ³	-	2.8	2.1	-	-	-	22.9
Successful judgments	-	18.6	9.8	-	2.5	-	-	30.9
Executed settlements	-	-	-	-	-	-	-	-
Agreed in principle settlements	-	9.0	-	-	-	-	-	9.0
Total income yet to be recognised ⁴ at 31-Dec-21	18.0	27.6	12.6	2.1	2.5	-	-	62.8
Total income ⁵ (recognised and yet to be recognised) in 1H22	27.7	63.0	23.5	42.2	1.9	20.0	-	178.3
provisionally attributable to OBL shareholders	28	-	-	11	<1	13	-	52
- provisionally attributable to NCI	-	63	24	31	1	7	-	126
Further income yet to be recognised (arising post 31-Dec-21)	-	-	30.0	11.7	54.5	2.9	-	99.1
EPV conversion in 1H22								
EPV of investments completed	58	225	41	515	60	33	-	932
Income conversion rate ⁵	14%	14%	10%	7%	-	38%	n/a	10%

- Investment income of \$115.5m recognised in 1H22 across the portfolio and comprises:
 - \$85.0m recognised from 31 fully completed investments which had an EPV of \$932m
 - \$28.4m recognised from partial completions and \$2.1m from completions in previous periods
- A further \$161.9m income yet to be recognised (\$62.8m at 31-Dec-21 plus \$99.1m arising post period end) relates to substantially completed investments with conditional settlements or judgments on appeal which will be recognised in future periods

1. Income recognised in 1H22 varies from the amount disclosed in the 2Q22 report due to accounting adjustments that occurred post the 2Q22 disclosure date.

2. Based on actual completions during the period and supersedes any previous announcements.

3 \$18m is the estimated future income that may flow from the existing settlement for Wivenhoe but that has not currently met IFRS income recognition criteria. It is currently anticipated to be recognised in FY22 or FY23 subject to the achievement of certain milestones in the settlement distribution process which are outside of our control. Collection of the existing receivable and this additional amount is anticipated to occur over the next 12 months with final payment anticipated in late 2022 or early 2023. Wivenhoe's EPV of \$253m, with anticipated completion in FY23, is included in the

group's total EPV assumptions on 31 December 2021.


4. Subject to change and may be recognised in FY22 or later.

5-Includes investments that fully completed in the period and the total income recognised over the investments' life and excludes partial completions in the period.

Cash

\$m Consolidated Group	1H21	1H22
Operational inflows		
Proceeds from litigation Investments – claims portfolio	8.2	7.
Proceeds from litigation Investments – purchased claims	-	3.
Proceeds from litigation Investments – intangibles	95.9	185.
	104.1	196.
Management fees	1.4	3.
Interest income	0.4	0.
	105.9	199.
Operational (outflows)		
Payments to suppliers and employees	(33.2)	(39.4
Income tax	(7.5)	(1.3
Other	(11.1)	(5.2
	(51.7)	(45.8
Net operational cashflows	54.1	153.
Investment (outflows)		
Payments for litigation investments – claims portfolio	(10.7)	(3.9
Payments for litigation investments – purchased claims	-	
Payments for litigation investments – intangibles	(67.0)	(40.0
Payments for litigation investments – capitalised overheads and employee costs	(3.9)	(3.
Interest paid – capitalised to litigation investments	(4.3)	(3.6
Investment outflows	(85.9)	(50.
Net NCI inflow / (outflow)		
Contributions from NCI	46.4	22.
Distributions to NCI	(36.6)	(106.6
	9.8	(84.)
Net increase/(decrease) in cash and cash equivalents	(21.9)	18.
Per Profit and Loss statement		
Management fees / net operational cash expenditure	3%	8
Net operational cash expenditure / net assets	8%	69
Net operational cash expenditure / investments	10%	8
Net operational cash expenditure / EPV	<1%	<10
Net assets	651.2	683
Headcount	172	18
Number of offices	18	2

\$m OBL financial capacity





- The above chart is for illustrative purposes only, no performance fees have been included in the analysis
- Estimated cash surplus of \$145m at end of FY22 is more than adequate to meet overheads and commitments
- Strong capital position to support corporate initiatives including:
 - the full transition towards a funds management model
 - organically funding our growth and future opportunities
 - meeting our deployment obligations
 - maintaining adequate liquidity commensurate to the global business needs
 - the potential to repay debt, pay dividends and buy back shares
- OBL is seeking a 5 year term facility of \$250m to be used for refinancing our bonds and notes¹ including establishing a \$100m delayed draw facility for working capital purposes, pay our fund commitments or for possible acquisition finance




Portfolio growth will drive future income generation

Increasing commitments and EPV improve operational efficiency





Commitments^{1,2} CAGR >43% \$m



1. Fund 5 and Fund 7 are not consolidated within the group financial statements. Here, Fund 5 is disclosed at 100%.

2. Includes conditional and Investment Committee approved investments.

3. Investment deployments includes capitalised overheads.

Other includes 1H22 impairments and foreign currency adjustment.



Provisional attribution future investment completions

	Possible completion period										
At 31-Dec-2021 \$m	6 mths to 30-Jun-22	FY23	FY24	FY25+	TOTAL						
Estimated portfolio value (EPV) ²											
Balance sheet	-	636	-	151	787						
Fund 1	164	1,111	258	289	1,821						
Funds 2&3	280	2,520	636	753	4,188						
Fund 4	37	417	2,832	1,997	5,283						
Fund 5	339	1,329	2,002	1,364	5,033						
Fund 6	144	837	695	1,695	3,370						
Total EPV	963	6,848	6,422	6,249	20,482						

At 31-Dec-2021 \$m Implied embedded value (IEV)	6 mths to 30-Jun-22	FY23 15% cc	FY24	FY25+ rate	TOTAL	Conversio	on rate 20%	Excluding impaired assets	12 d coi
Balance sheet	-	95	-	23	118	79	157	43	
Fund 1	25	167	39	43	273	182	364	273	
Funds 2&3	42	378	95	113	628	419	838	523	
Fund 4	6	63	425	299	792	528	1,057	573	
Fund 5	51	199	300	205	755	503	1,007	755	
Fund 6	22	125	104	254	506	337	674	506	
Total IEV	145	1,027	963	937	3,072	 2,048	4,096	2,672	
IEV attributable to NCI	128	498	678	617	1,921	1,339	2,503	1,730	
IEV attributable to OBL	17	529	285	320	1,151	709	1,593	942	
Management fees to OBL	3	7	14	35	59				
Total to OBL	20	536	299	355	1,210				

~\$1.2bn provisionally attributable to OBL based on the realisation of our current pipeline of investments, assuming they occur in line with past performance at 15% conversion, including management fees.

For second generation funds (plus Fund 6) the IEV attribution does not include any performance fees given it is infeasible to calculate these.

Any performance fees arising will result in a transfer of IEV attribution from NCI to OBL.

IEV sensitivities

2 month delay of mpletior dates

118

273

628 792

755

506 **3,072**

1,946 1,126


Duration risk has traditionally been addressed through a time based pricing escalator. Historically these capped out at a certain level, leaving us exposed to further delays. We have sought to address the risk by incorporating some additional IRR protection provisions. The 12 month delay sensitivity does not incorporate the effects of these duration protections and assumes the income is the IEV at whatever time it is received.


Please see the notes on slide 14 which accompany this slide and the Glossary at <u>https://omnibridgeway.com/investors/omni-bridgeway-glossary</u> which includes key concepts.


Both the notes and the Glossary should be read in conjunction with this presentation.

Balanced portfolio created by diversified EPV

- EPV grew to \$23.2 billion¹ at 31 December 2021
- Diversification provides mitigation to risk of competition and regulatory intervention and portfolio concentration








Global class action investments represent 29% of our portfolio (15% Australia, 14% RoW)





Direct balance sheet is in 'run off' as we continue our transition to a fund management model, whereby investments are funded through dedicated investment vehicles with global co-investors and joint venture structures

Portfolio summary

					Amounts att to inves		Amounts attr to Omni Brio				Current i	nvestments ²					Complet	ted investments ³			
																		Succe	ss rate		
	At 31-Dec-2021	Launch date	Fund size	Committed	Capital	Returns ¹	Capital	Fees		#	Average duration	EPV	IEV	#	Average duration	EPV	EPV conversion rate	outcome ⁴	Financial outcome ⁴ \$ weighted average	ROIC⁵	IRR ⁵
	Fund 1	Feb-2017	USD172m	100%	-	\$37m	\$57m	\$8m		19	5.1 yrs	\$1,821m	\$273m	29	3.0 yrs	\$1,526m	13%	90%	76%	65%	25%
	Funds 2&3	Oct-2017	AUD189m	100%	\$69m	\$35m	\$28m	\$4m		27	2.6 yrs	\$4,188m	\$628m	15	1.5 yrs	\$438m	17%	80%	49%	83%	105%
Q	Fund 4	Apr-2019	USD500m	46%	\$183m	-	\$46m	-		20	1.0 yrs	\$5,283m	\$792m	5	0.7 yrs	\$713m	9%	100%	100%	35%	145%
	Fund 5	Sept-2019	USD500m	46%	\$91m	-	\$23m	-		40	1.0 yrs	\$5,033m	\$755m	4	0.9 yrs	\$131m	20%	75%	96%	28%	18%
	Fund 6 ⁶	Jan-2017	EUR150m	99%	\$104m	-	\$5m	-	1	80	5.6 yrs	\$3,370m	\$506m	190	3.1 yrs	n/a	n/a	n/a	77%	331%	160%
	Fund 7	Jul-2019	USD100m	-	\$5m	-	<\$1m	-		-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Ű	Fund total				\$452m	\$72m	\$160m	\$12m	2	86	4.3 yrs	\$19,695m	\$2,954m					I			
-	Balance sheet				-	-	-	-		11	7.0 yrs	\$787m	\$118m	94	3.1 yrs	\$3,268m	21%	85%	76%	135%	84%
	Portfolio total				\$452m	\$72m	\$160m	\$12m	ž	.97	4.4 yrs	\$20,482m	\$3,072m								

Fund 1 and Funds 2&3 are fully committed; all are in harvest mode. Given the respective fund structure, the NCI have priority entitlement to distribution of capital and preferred returns, recourse only to the investments within the respective Funds. There are a substantial number of investments and associated EPV within each of those Funds from which those priority entitlements can be met.

Funds 4 and 5 are 46% committed. The investment periods complete four years from commencement, with a run-off harvest period that follows.

Funds 6 and 7 are structured on a combined investment and Fund waterfall basis except that with respect to Fund 7, funds are first allocated towards the NCI debt before allocations are made via the waterfall. Fund 7 is being restructured with the aim to have it funded by and included in the new Fund 8. The allocation of capital to Fund 7 from Fund 6 is then extinguished.

1. Returns for Funds 1 – 3 include accumulated preferred returns, special distributions and investor undrawn fee.

2. Excludes conditional investments and Investment Committee approved investments.

5. Return on invested capital (ROIC) and internal rate of return (IRR) is measured before capitalised overheads and operating overheads.

6. All data for Fund 6 is at 30 September 2021 except current investments data.

Fund 5 and Fund 7 are not consolidated within the group financial statements. Here they are disclosed at 100%.

Highlights

Financial results

Portfolio performance

Strategy

^{3.} Data covers the period from 1 July 2011 for the balance sheet investments and each of the Funds from their dates of inception.

^{4.} A successful legal outcome is one where the client wins a return through settlement or judgment; a successful financial outcome requires the Group's income to exceed investment costs



Creating value through our diversified model

Strategic focus on growth in US market, with a target to double commitments

Strategic priorities and targets ¹	Status at 31 December 2021	
FY22 commitments of ~\$520m with ~\$330m in deployments of which OBL's contribution is ~\$65m	\$190m commitments made in 1H22, representing \$4.8bn EPV and approximately 37% of our FY22 target, across 31 new investments and 16 conditionally funded investments	FY25 target ¹
	\$151m new investment opportunities, across 29 exclusive term sheets with clients, which if converted into funded investments represents a further 29% of FY22 target	\$5bn FUM\$1bn annual commitments
Launch Fund 8 (enforcements) with €300 million capital raising	Investment opportunities identified prior to 31 December 2021 will continue to flow into Fund 6 during an agreed run off period to 30 June 2022	
	From 1 January 2022, European merits investment opportunities identified will flow into Fund 5 and enforcement opportunities identified will be warehoused by OBL until Fund 8 is established, which is expected before 30 June 2022	Key short-term drivers
Refinance debt to improve capital efficiency	With commercial terms finalised, the refinancing of our debt facilities remains on track to occur in 2022, subject to completing final legal due diligence, documentation and syndication	of our business are: • Investment completions
		Growth in commitments
Grow our FY22 US commitment target to \$225m in new investments, up 105% from FY21	\$59m commitments made in 1H22, representing approximately 26% of our FY22 target, plus \$79m exclusive term sheets across 13 new investment opportunities which if converted into funded investments represents a further 35% of US FY22 target	
Expand geographically with one new office, most likely in Washington DC or Boston, support our "boots on ground" approach	Establishment of our Washington DC presence in February 2022	Relevant long term metrics are:
Diversify the portfolio through new product offerings in the US	Key appointments were made to launch our global enforcement business and antitrust team in the US including the role of Senior Investment Manager - Director of Enforcement– US	Achievement of 5-year business plan targets
Improve US efficiency ratios of term sheet conversion, days in due diligence and funds committed per investment manager	16 executed term sheets in 1H22 (v 15 in FY21) 7 investment funding approvals (v 9 in FY21)	 Growth of resources to support our business and enhance our capability
Employ more sophisticated risk management tools	Exploring portfolio insurance products, but these have not yet been utilised	Expansion of products
Expand headcount from 20 to 50 by end of FY22	30 headcount with 7 appointments made during 1H22 to enhance our capability. New hires, who have not yet begun working, will increase the headcount to 37 in March 2022	and diversification of risk




nlv Annexure **NS** onal Ň



Provisional attribution future investment completions Assumptions and notes

Refer to slides 9 and 17



- EPV of impaired assets excluded from EPV with commensurate flow-on to IEV and attribution
- PCP on all Portfolio Investments is delayed by 12 months

Management fee assumptions:

The estimated management fees are based upon aggregated anticipated budgeted investment deployment for Funds 4, 5 and 6

Notes

Possible completion period (PCP):

- PCP is a dynamic concept and is subject to regular review and updating to take account of the circumstances of the underlying investment
- It is to be expected that the PCP for some investments within the portfolio will be adjusted at each reporting date
- PCP is not necessarily the same as anticipated IFRS income recognition period governing income recognition rules

Estimated portfolio value (EPV) assumptions:

- EPV includes all Portfolio Investments, which includes, irrespective of impairment, investments which have had a negative award or judgment but nonetheless the Group believes have positive prospect s of success on appeal
- At 31 December such investments included Wivenhoe (\$253m in FY23), Westgem (\$250m in FY23), and a Fund 4 investment in FY24
- Also included at 31 December was Novo Nordisk (\$702m in FY23) which subsequently settled and was impaired to reflect no recovery of the deployed capital
- Conditionally funded and IC approved investments are not included in the EPV

Fund summary

		Capital calle	d			Uncalled capital		Accumulated preferred return	Accumulated special distribution	Accumulated management fee
FUND 1 USA	USD million	Total	Investor	Omni	Total	Investor	Omni	Investors	Investors	Omni
Launched Feb-17		166.7	125	41.7	5.0	3.8	1.2	49.3	1.8	5.6
Size: USD172m	Distributions	(125.0)	(125.0)		n/a	n/a	n/a	(24.4)	-	-
	Total USD	41.7	-	41.7	5.0	3.8	1.2	24.9	1.8	5.6
	AUD equivalent	57.5	-	57.5	6.8	5.2	1.7	34.3	2.5	7.7

FUNDS 2&3		Capital calle	ed			Uncalled capital		Accumulated preferred return	Accumulated special distribution	Accumulated management fee
REST OF WORLD	AUD million	Total	Investors	Omni	Total	Investors	Omni	Investors	Investors	Omni
Launched Oct-17		138.5	110.8	27.7	50.1	40.0	10.1	29.2	5.7	4.0
Size: AUD189m	Distributions	(41.6)	(41.6)	-	n/a	n/a	n/a	-	-	-
	Total AUD	96.9	69.2	27.7	50.1	40.0	10.1	29.2	5.7	4.0

			Capital call	ed			Uncalled capital			Recycled proceeds	
_		USD million	Total	Investors	Omni	Total	Investors	Omni	Total	Investors	Omni
\cap	FUND 4 USA		208	166.4	41.6	292.0	233.6	58.4	-	-	-
	Launched Apr-19			n/a	n/a	n/a	n/a	n/a	-		
1	Size: USD500m	Distributions	(42.4)	(33.9)	(8.5)	-	-	-	-	-	-
11		Total USD	165.6	132.5	33.1	292	233.6	58.4	-	-	-
		AUD equivalent	228.5	182.8	45.7	402.9	322.3	80.6	-	-	-

		Capital call	ed			Uncalled capital		Recycled proceeds			
FUND 5	USD million	Total	Investors	Omni	Total	Investors	Omni	Total	Investors	Omni	
REST OF WORLD		93.7	76.6	17.1	406.3	323.4	82.9	-	-	-	
Launched Sept-19			n/a	n/a	n/a	n/a	n/a	2.5	2.0	0.5	
Size: USD500m	Distributions	(11.7)	(11.0)	(0.7)	n/a	n/a	n/a	-	-	-	
	Total USD	82	65.6	16.4	406.3	323.4	82.9	2.5	2.0	0.5	
	AUD equivalent	113.1	90.5	22.6	560.6	446.2	114.4	3.4	2.8	0.7	

		Capital call	ed			Uncalled capital		Recycled proceeds			
FUND 6	EUR million	Total	Investors	Omni	Total	Investors	Omni	Total	Investors	Omni	
Launched Jan-17		70.0	66.5	3.5	80.0	76.0	4.0	-	-	-	
	Distributions		n/a	n/a	n/a	n/a	n/a	39.3	37.4	2.0	
	Total EUR	70.0	66.5	3.5	80.0	76.0	4.0	39.3	37.4	2.0	
	AUD equivalent	109.2	103.7	5.5	124.8	118.6	6.2	61.4	58.3	3.1	

		Capital call	ed			Uncalled capital			Recycled proceeds	
	USD million	Total	Investors	Omni	Total	Investors	Omni	Total	Investors	Omni
FUND 7 Launched Jul-19		3.6	3.5	0.1	96.4	91.5	4.8	-	-	-
Size: USD100m	Distributions	0	0.0	0.0	n/a	n/a	n/a	-	-	-
	Total USD	3.6	3.5	0.1	96.4	91.5	4.8	-	-	-
	AUD equivalent	5.0	4.8	0.2	132.9	126.3	6.6	-	-	-

Non-controlling interests (NCI)

\$m	Fund ¹	Funds 2&3	Fund 4	Fund 5	Fund 6	Total
Opening 30-Jun-21	(147.5)	(80.4)	(85.1)	-	(117.5)	(430.5)
Called during the period	-	(16.0)	(6.4)	-	<1	(22.4)
Distributed during the period	80.2	<1	19.0	-	<1	99.2
Accumulated preferred return and special distribution (shown as movement in equity)	(4.4)	(6.0)	-	-	-	(10.3)
Accumulated during the period	<1	-	(1.1)	-	(1.1)	(2.2)
Closing 31-Dec-21	(71.6)	(102.4)	(73.6)	-	(118.6)	(366.2)
Capital remaining available to be called (NCI & parent interest)	6.8	50.1	402.9	-	124.8	584.6
Remaining number of cases (NCI & parent interest)	19	27	20	40	180	286
Remaining EPV (NCI & parent interest)	1,821	4,188	5,283	-	3,370	14,662
Distribution history						
2H17	-	-	-	-	-	-
1H18	-	-	-	-	-	-
2H18	4.3	-	-	-	-	4.3
1H19	5.1	-	-	-	-	5.1
2H19	13.3	4.0	-	-	-	17.3
1H20	37.8	-	3.3	-	-	41.1
2H20	20.0	10.6	-	-	-	30.6
1H21	10.9	26.5	1.9	-	0.2	39.5
2H21	25.3	0.5	-	-	-	25.8
1H22	80.2	<1	19.0	-	<1	99.2
Total distributions	196.9	41.6	24.2	-	0.2	262.9

- First generation funds remain within the 100% proceeds distribution to NCI stage of the waterfall
- First generation funds have cash distributions still to be paid to NCI in respect of the result
- Fund 6 have retained and recycled proceeds into investments during the period



Impairment update

- Several investments have been impaired to comply with our policy and accounting standards, even though, for some, the legal processes (via appeals) continue
- Wivenhoe, Westgem and a Fund 4 investment have positive prospects of success on appeal, as such these investments are retained in full in our analysis of EPV
- There is no cash impact in this period

Novo Nordisk (EPV \$702m in FY23) – settlement reached in January 2022

- Investment of \$1.8m has been impaired to zero in 1H22
- ✓ \$9.8m security for costs has been returned
- The finalisation of this investment has released approximately \$19m capacity back to Funds
- The associated IEV of \$105m is currently included in the portfolio EPV assumptions at 31-Dec-2021 and as such the outcome of this settlement will be updated in the 30-Mar-22 disclosure

Wivenhoe (EPV \$253m in FY23) - the special leave application oral hearing will not be listed before April 2022

\$95.3m income recognised in FY21 from 50% of the investment with an additional \$18m¹ income yet to be recognised that may flow from the existing settlement and anticipated –to be collected over next 12 to 15 months

The settlement of the remaining 50% portion of the liability allocated to Seqwater, subject to appeals and other court processes, represents potential upside of \$85m estimated future income

- Investment of \$20.6m was impaired in 1H22 with approximately \$1.4m remaining on balance sheet
- No adverse cost risk nor ongoing costs if successful on appeal

Westgem (EPV \$250m in FY23) - appeal hearing is listed for 4 to 8 April 2022

- Investment of \$58.5m has been impaired to zero (\$58.1m in FY21,\$0.4m in 1H22), with a net (after insurance cover) provision of \$8.7m raised for potential adverse cost exposure
- Senior counsel advise that the merits of the appeal are positive with possible investment completion in FY23
- If appeals succeed, the impairment, adverse cost provisioning and P&L impact will be reversed in whole or in part, depending on the final decision
- The only future cash impact will be for the uninsured portion adverse cost exposure which is estimated to be \$8.7m plus the costs and adverse costs of the appeal if the appeal fails

Fund 4 Investment (EPV undisclosed in FY24) – appeal took place on 19 January 2022, awaiting decision as the appeal court reserved judgment

- Investment of \$56.8m was impaired (\$54.8m in FY21,\$2.0m in 1H22)
- There is no adverse cost exposure
- Legal advice on prospects of the appeal is positive with possible investment completion in FY24
- If appeal succeeds, the impairment and P&L impact will be reversed
- There is no future cash impact if the appeal fails

1, \$18m income yet to be recognised is the estimated future income that may flow from the existing settlement but that has not currently met IFRS income recognition criteria.

OMNI BRIDGEWAY

Balance sheet, Fund 1 and Funds 2&3 cash generation^{1,2}

Implied embedded value (IEV) attribution		FUND 1			FUNDS 2&34		Estimated portfolio value (EPV) Possible completion profile							
At 31-Dec-21	10% EPV conversion	15% EPV conversion	20% EPV conversion	10% EPV conversion	15% EPV conversion	20% EPV conversion	At 31-Dec-21	# Investments	6 mths to 30-Jun-22	FY23	FY24	FY25+	Total	Fin
Called capital	US\$125.0m	US\$125.0m	US\$125.0m	\$110.8	\$110.8	\$110.8	Balance sheet	11	-	\$636m	-	\$151m	\$787m	ancia
Accumulated preferred return	US\$49.3m	US\$49.3m	US\$49.3m	\$29.2	\$29.2	\$29.2	Fund 1	19	\$164m	\$1,111m	\$258m	\$289m	\$1,821m	al res
Accumulated special distribution	US\$1.8m	US\$1.8m	US\$1.8m	\$5.7	\$5.7	\$5.7	Funds 2&3	27	\$280m	\$2,520m	\$636m	\$753m	\$4,188m	ults
Subtotal	US\$176.1m	US\$176.1m	US\$176.1m	\$145.7	\$145.7	\$145.7								
Less: distributions	US\$149.4m ³	US\$149.4m ³	US\$149.4m ³	\$41.6	\$41.6	\$41.6								Ρ
Net attributable to NCI	US\$26.7m	US\$26.7m	US\$26.7m	\$104.1	\$104.1	\$104.1	realised today in line with past performance					ortfol		
Net attributable to NCI (AUD equivalent)	\$36.8m	\$36.8m	\$36.8m	\$104.1m	\$104.1m	\$104.1m						Portfolio performance		
Less: implied embedded value (EPV x conversion rate)	\$182.1m	\$273.2m	\$364.2m	\$418.8m	\$628.2m	\$837.7m	OBL wou	uld expect to	generat	e appro	ximatel	у		rform
IEV in excess of NCI	\$145.3m	\$236.4m	\$327.4m	\$314.7m	\$524.1m	\$733.6m	\$470	million t	o \$1	billior	า			lance
OBL called capital	\$57.5m	\$57.5m	\$57.5m	\$27.7m	\$27.7m	\$27.7m								
OBL accumulated management fee (life to date)	\$7.7m	\$7.7m	\$7.7m	\$4.0m	\$4.0m	\$4.0m								
Subtotal	\$65.3m	\$65.3m	\$65.3m	\$31.7m	\$31.7m	\$31.7m								Ś
Residual implied embedded value	\$80.0m	\$171.1m	\$262.1m	\$283.0m	\$492.4m	\$701.9m								Strategy
Residual profit share % to OBL	85%	85%	85%	80%	80%	80%	В	ALANCE SHEET		TC	OTAL CASH G	ENERATION		gy
Residual profit share to OBL	\$68.0m	\$145.4m	\$222.8m	\$226.4m	\$393.9m	\$561.5m	10% EPV conversion	15% EPV conversion c	20% EPV onversion	10% EP conversio		6 EPV rsion	20% EPV conversion	
Cash generation to OBL	\$133.3m	\$210.7m	\$288.1m	\$258.1m	\$425.6m	\$593.2m	\$78.7m	\$118.0m	\$157.4m	\$470m	\$754r	m \$	1,039m	

1. This analysis is not earnings guidance or a forecast. Past performance is not necessarily an indicator of future performance. This analysis is based on the hypothetical scenario of all of the portfolio investments completing at the long term completion rate to their respective EPV at

31 December 2021. In practice, the portfolios will complete over multiple time periods and the interim EPVs may vary and they may ultimately complete below or above the LTCR. Prior to the full return of capital to the investors, preferred return will continue to accrue.

2. The analysis ignores possibility of further capital calls being required.

3. Excludes cash on hand.

4. See slide 17 for additional context on Novo Nordisk impairment.

Highlights

OBL value > second generation funds (Fund 4, Fund 5)

Indicative analysis¹ of the second generation funds' return to OBL parent entity based on illustrative example

Example investment return

		Investme	nt
		Via Fund	Direct
Claim size	А	\$100.0m	\$20.0m
Invested capital	В	\$10.0m	\$2.0m
Litigation life	С	3 years	3 years
Return from win	D	30%	30%
Proceeds from win	E=Ax50% ²	\$50.0m	\$10.0m
Investment income	F=(D*E)+B	\$25.0m	\$5.0m
Investment IRR		57%	57%
Investment ROIC		150%	150%
OBL ownership interest	G	20%	100%
OBL contribution to invested capital	BxG	\$2.0m	\$2.0m
OBL share of investment income	FxG	\$5.0m	\$5.0m
OBL performance fee	based on waterfall	\$3.2m	n/a
OBL investment return		\$8.2m	\$5.0m
OBL management fee %		2%	n/a
OBL management fee	on invested capital deployed	\$0.3m	n/a
Total to OBL		\$8.5m	\$5.0m
OBL IRR		98%	57%
OBL ROIC		325%	150%

Estimated portfolio value and implied embedded value

	Possible completion EPV								
At 31-Dec-2021	# Investments	Deployed capital	EPV	6 mths to 30-Jun-22	FY23	FY24	FY25+	IEV	
Fund 4	20	US\$134m	\$5,283m	\$37m	\$417m	\$2,832m	\$1,997m	\$792m	
Fund 5	40	US\$64m	\$5,033m	\$339m	\$1,329m	\$2,002m	\$1,364m	\$755m	

• Based on the example investment return "via Fund" OBL contributes 20% of the invested capital and receives ~34% of the investment income, including the 2% management fee on the invested capital deployed

• Each Fund has considerable EPV, IEV and significant additional capacity available to make new investments to generate substantial returns to both OBL and Fund investors (NCI)



OBL value > purchased funds (Fund 6, Fund 7)

Indicative analysis of the fund return value to OBL parent entity based on based on current portfolio

Return profile

\$m At 31 December 2021	Number	Cost	Purchase price adjustment	Consolidated total	EPV
Acquisition date	178	59.8	103.5	163.4	
Additions	0	8.8	0.3	9.1	
Completions	(53)	(9.5)	(16.5)	(26.1)	
Withdrawn / terminated	(2)	<0.1	<0.1	<0.1	
Other costs	-	-	-	-	
FX adjustment	-	(1.9)	(3.4)	(5.3)	
Net acquired portfolio	123	57.2	83.9	141.1	1,670
IEV on acquired portfolio					251
Additions	63	18.7	n/a	18.7	
Completions	(6)	(1.7)	n/a	(1.7)	
Withdrawn / terminated	-	-	n/a	-	
Other costs	-	-	n/a	-	
FX adjustment	-	-	n/a	-	
Net new portfolio	57	17.0	n/a	17.0	1,702
IEV on new portfolio					255
Total IEV					506


Estimated portfolio value and implied embedded value

			Possible completion EPV								
At 31-Dec-21	# Investments	Deployed capital	EPV	FY22	FY23	FY24	FY25+	IEV			
Fund 6	180	€67m	\$3,370m	\$144m	\$837m	\$695m	\$1,695m	\$506m			

- The remaining portion of Fund 6 investment portfolio that existed at the time of the November 2019 acquisition of OBE is carried at acquisition cost less impairment which was \$141.1m at 31 December 2021
- The EPV and IEV of the portfolio can be utilised the same way as in the OBL raised funds; with the income subject to waterfall arrangements depending upon the nature of underlying investment
- Historically in Fund 6, ~25% of the proceeds from completed investments have been attributed to OBE this is an overall average that does vary by investment type

Fund 6¹ structure

- OBL through OBI (of which OBH has a 100% interest in) is a 5% co-investor, alongside a third party LP in Fund 6 (OB Capital)
- OB Capital holds B-shares in OBBV which consolidates various subsidiaries in which cases are contracted and held
- The B-shares oblige Fund 6 to finance A-C-case investments as well as pay a Management and Service Contribution to cover costs of management services and legal and research services, and entitle Fund 6 to receive pre-defined returns on A, B and C-cases
- The A-shares oblige OBH to finance D-case investments and any costs not specifically covered by Fund 6 under the B-shares and entitle OBH to receive returns not specifically allocated to Fund 6 under the B-shares
- All distributions to Fund 6 are subsequently distributed to LPs in accordance with a European waterfall structure



Annexure

Fund 6¹ summary

Gaso turoca	· · · · · · · · · · · · · · · · · · ·	Fund 6 obligations ¹	Fund 6 entitlements ¹	
Case types		Fund 6 obligations ¹		After individual case level waterfalls
A-cases	New merits funding investments	Funding 100% of investments	100% of case profit	 Return of all capital to LPs Preferred return hurdle of 10% to LPs
B-cases	Full historical (pre-Fund 6) portfolio of merits and enforcement investments All new pure enforcement investments	Funding 100% of investments going forward (but not of historical costs for historical portfolio)	20% IRR based on Fund 6 case investment	 3. Catch-up to carried interest investor (ie, catch up of performance fee over hurdle return) 4. Split between LP investors and carried interest investor (i performance fee): a) IRR >10% but <20%: 20%
C-cases	Select set of four historical (pre-Fund 6) investments	Acquisition at 2 x historical investments, plus funding 100% of investments going forward	Profit based on each party receiving equal case IRR	b) IRR >20%: 30% OBH A-shares
D-cases	Balance sheet investments	0%	0%	Profit not specifically allocated to the B-shares of Fund 6 ¹ including income on B-cases in excess of 20% IRR and the IRF equalisation income on C-cases
		Annual Management and Service Contribution at agreed level based on prior budget and auditor reviewed		

Fund 6 summary financials

Fund 6, OBBV cash income, Management and Service Contribution

- From merger completion¹ to 31-Dec-21, OBBV has realised EUR43m in cash income on the portfolio of investments in which Fund 6 and the EMEA balance sheet participates
- Of this, EUR13m in revenues was attributable to OBH (ie, not part of Fund 6 entitlement as per the B-shares)
- In addition, over EUR1m in revenues have been realised on the D-cases (EMEA balance sheet cases), which are fully attributed to OBH and which is not part of the Fund 6 reporting
- Therefore, over EUR14m has been directly received by Omni Bridgeway by way of its case specific investment profit share
- We have also charged / will charge EUR17m in Management and Service Contribution over this period which has been received / is receivable from Fund 6 / B-shares

Recycling

- OBBV will only distribute after tax profits on the B-shares to OB Capital if it has more cash than expected to be required in the short term for:
 - deployments on existing and new investments
 - Management and Service Contribution
- This has not yet happened as the portfolio has been growing
- Any after tax profits that will be distributed to OB Capital will have to be distributed as per the European waterfall structure (ie, first full repayment of capital and hurdle)
- Distributing early to OB Capital and subsequently calling new capital to meet financing obligations will therefore make no difference

Accounting

- All case revenues, investments and all costs of OBBV are fully consolidated into OBL
- Fund 6 cash contribution for financing obligations to OBBV under the B-shares are accounted for as share premium contributions on the B-shares
- The Management and Service Contribution is not accounted for as a revenue
- Capital contributed, plus profits from matters less Management and Service Contribution under the B-shares, is accounted for in the consolidated accounts as non-controlling interest
- The remaining portion of Fund 6 investment portfolio that existed at the time of the November 2019 acquisition of OBE is carried at acquisition cost less impairment

Regulatory reforms

- Continued push for regulatory reform for litigation finance industry in Australia, Europe and US
 - We have consistently been and will continue to be an advocate for fit for purpose regulation of the industry

US

• No material changes anticipated

Europe

- Committee on Legal Affairs report of 17 June 2021 by EU Parliament member Axel Voss (Voss Report)
- Ongoing process with responses provided to the committee
- Voss Report relied heavily on the misinformation in the now deferred Australian process

Australia

- Class action reform legislation, which was introduced into Parliament in 2021 (but has not yet been passed by the Senate), has been delayed until after the Federal election
- A number of the major measures announced to date have been supported by OBL which include the requirement for litigation funders to hold an ASFL and for class actions to be registered under the managed investment scheme regime and as such this has reduced the number of funders that are able to operate





OMNI BRIDGEWAY



Disclaimer

- The material in this presentation has been prepared by Omni Bridgeway (OBL) and is general background information about Omni Bridgeway's activities. The information is given in summary form and does not purport to be complete.
- A number of terms used in this presentation including: ROIC, EPV, IEV, net cash generation, operational cash expenditure, success rate on dollar weighted average, IRR and actual and budgeted commitments are categorised as non-IFRS information prepared in accordance with ASIC Regulatory Guidance 230 Disclosing non-IFRS financial information, issued in December 2011. This information has not been audited or reviewed by BDO unless expressly stated. For further commentary and analysis refer to Omni Bridgeway's 2022 Interim Financial Report.
- This presentation contains certain forward-looking statements that can generally be identified using forward looking words such as, "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target" and other similar expressions. Estimates of, indications of, and guidance or outlook on, future earnings or financial position or performance are also forward looking statements. Forward looking statements involve risks and uncertainties. Forward looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee or future performance. Forward looking statements involve known and unknown risks, uncertainties, assumptions, and contingencies which are subject to change without notice, as are statements about market and industry trends which are based on interpretations of current market conditions. Actual results, performance or achievements may vary materially from any forward looking statements and the assumptions on which statements are based. Except as required by law or regulation, OBL disclaims all obligations to update publicly any forward looking statements, whether as a result of new information, future events, or results or otherwise.
- This presentation is provided for general information purposes. The information in this presentation does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for or purchase any Omni Bridgeway securities. Neither the information in this presentation nor any part of it shall form the basis of or be relied upon in connection with any future offer of Omni Bridgeway securities or act as an inducement to enter into any contract or commitment whatsoever.
- To the maximum extent permitted by law, no representation or warranty is given, express or implied, as to the accuracy of the information contained in the presentation.
- The information in this presentation is not investment advice and has been prepared without taking into account your investment objectives, financial situation or particular needs (including financial and taxation issues). It is important that you read and consider the terms of any Omni Bridgeway securities in full before deciding to invest in such securities and consider the risks that could affect the performance of those securities.
- 🔨 If you have any questions, you should seek advice from your financial adviser or other professional adviser before deciding to invest in Omni Bridgeway securities.
- By providing the material in this presentation Omni Bridgeway is not in any way making forecasts, predictions or providing earnings guidance and nothing in this presentation should be relied on as doing so.
- All figures are in Australian Dollars (AUD, A\$) unless otherwise stated.
- US Ownership Restriction the ordinary shares of Omni Bridgeway are subject to ownership restrictions applying to residents of the United States. For further information, see the Investors section of our website or click https://omnibridgeway.com/investors/us-ownership-restriction

25



This is presentation is authorised for release to the market by the Board.

600 Bourke Street Melbourne VIC 3000

ASIA	AUSTRALIA		CANADA	EUROPE, MIDDLE EAST & AR	/IDDLE EAST & AFRICA			CA
Hong Kong +852 3978 2629 Level 27 World-Wide House 19 Des Voeux Road Central Central, Hong Kong Singapore +65 6813 2647 Level 13-03 6 Battery Road Singapore 049909	Adelaide +61 8 8122 1010 50 Gilbert Street Adelaide SA 5000 Brisbane +61 7 3108 1311 Level 7, The Annex 12 Creek Street Brisbane City QLD 4000 Melbourne +61 3 9913 3301 Level 3 Bourke Place	Perth +61 8 9225 2300 Level 6 37 St Georges Terrace Perth WA 6000 Sydney +61 2 8223 3567 Level 7 35 Clarence Street Sydney NSW 2000	Montreal +1 514 257 6971 60 rue St-Jacques Bureau 401 Montréal QC H2Y 1L5 Toronto +1 416 583 5720 250 The Esplanade Suite 127 Toronto ON M5A 1J2	Amsterdam +31 70 338 4343 Schiphol Boulevard 121 1118 BG Schiphol Amsterdam The Netherlands Cologne +49 221 801155-0 Gereonstr. 43-65 50670 Cologne Germany	Geneva +41 22 818 6300 Rue de la Rôtisserie 4 1204 Geneva Switzerland London +44 203 968 6061 5 Chancery Lane London WC2A 1LG United Kingdom	Dubai +971 4 514 4608 Unit 1905, Level 19 Index Tower Dubai International Financial Centre 507152 Dubai United Arab Emirates	Houston +1 713 965 7919 LyondellBasell Tower 1221 McKinney Street Suite 2860 Houston TX 77010 Los Angeles +1 213 550 2687 555 W. Fifth Street Suite 3310 Los Angeles CA 90013	New York +1 212 488 5331 437 Madison Avenue 36th Floor New York NY 10022 San Francisco +1 415 231 0363 50 California Street Suite 2550 San Francisco CA 94111

ersonal